Case Study: Supporting Global Delivery of a Phase III Cardiovascular Outcomes Trial for a Global Top-10 Pharmaceutical Company
Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population
Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularly in patients with recent acute coronary syndrome (ACS) events. This case study highlights how a global, integrated delivery model supported the execution of a Phase III diabetes CVOT across 26 countries and more than 700 sites. Leveraging deep cardiometabolic expertise, accelerated startup strategies, targeted recruitment, and rigorous global oversight, the program enabled rapid activation, sustained enrollment, and high-quality, adjudicated data generation.
Download the full case study to explore how we support complex diabetes and cardiovascular clinical trials.
Related resources
Peer Reviewed Publication: LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized TrialPatients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
Case Study: Accelerating Performance in a Phase III CVOT Rescue Program for a Mid-Size Biotech
Rescuing a Stalled Cardiovascular Outcomes Trial Through Targeted Operational Intervention When a Phase III cardiovascular outcomes trial (CVOT) faced significant enrollment delays and timeline risk, Julius Clinical was engaged to support and acc...